Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)

BPS Bioscience

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)

7

Neutralisation/Blocking

Research Use Only

The functional titer of SARS-CoV-2 Spike Pseudotyped Lentivirus (~1-2 x 105 TU/ml) is significantly lower than VSV-G pseudotyped lentivirus (>107 TU/ml), although the amount of lenti particles are similar (>109 LP/ml). The exact titer is provided with eac

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2.

-80°C

12352202